{"id":"https://openalex.org/W2083338868","doi":"https://doi.org/10.1089/10445460152595577","title":"An Open-Label, Dose-Ranging Study of Atomoxetine in Children with Attention Deficit Hyperactivity Disorder","display_name":"An Open-Label, Dose-Ranging Study of Atomoxetine in Children with Attention Deficit Hyperactivity Disorder","alternate_titles":[],"publication_year":2001,"publication_date":"2001-09-01","ids":{"openalex":"https://openalex.org/W2083338868","doi":"https://doi.org/10.1089/10445460152595577","mag":"2083338868","pmid":"https://pubmed.ncbi.nlm.nih.gov/11642475"},"language":"en","primary_location":{"id":"doi:10.1089/10445460152595577","doi":"https://doi.org/10.1089/10445460152595577","is_oa":false,"landing_page_url":"https://doi.org/10.1089/10445460152595577","pdf_url":null,"source":{"id":"https://openalex.org/S198272637","display_name":"Journal of Child and Adolescent Psychopharmacology","issn_l":"1044-5463","issn":["1044-5463","1557-8992"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320443","host_organization_name":"Mary Ann Liebert, Inc.","host_organization_lineage":["https://openalex.org/P4310320443","https://openalex.org/P4310320017"],"host_organization_lineage_names":["Mary Ann Liebert, Inc.","SAGE Publishing"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Child and Adolescent Psychopharmacology","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2083338868"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5091444284","display_name":"Thomas Spencer","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Thomas Spencer","raw_affiliation_strings":["Pediatric Psychopharmacology Unit, Massachusetts General Hospital, Boston 02114, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pediatric Psychopharmacology Unit, Massachusetts General Hospital, Boston 02114, USA","institution_ids":["https://openalex.org/I4210087915"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5070269405","display_name":"Joseph Biederman","orcid":"https://orcid.org/0000-0001-8233-663X","observed_orcids":["https://orcid.org/0000-0001-8233-663X"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Joseph Biederman","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5032744893","display_name":"John H. Heiligenstein","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"John Heiligenstein","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000660066","display_name":"Timothy E. Wilens","orcid":"https://orcid.org/0000-0002-5749-8503","observed_orcids":["https://orcid.org/0000-0002-5749-8503"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Timothy Wilens","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5070178181","display_name":"Douglas E. Faries","orcid":"https://orcid.org/0000-0001-8952-7738","observed_orcids":["https://orcid.org/0000-0001-8952-7738"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Douglas Faries","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028349876","display_name":"Jefferson B. Prince","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Jefferson Prince","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5052145058","display_name":"Stephen V. Faraone","orcid":"https://orcid.org/0000-0002-9217-3982","observed_orcids":["https://orcid.org/0000-0002-9217-3982"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Stephen V. Faraone","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086143988","display_name":"Jackie Rea","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Jackie Rea","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5021247377","display_name":"Jennifer Witcher","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Jennifer Witcher","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5004655396","display_name":"Stephanie Zervas","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Stephanie Zervas","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":7.0307,"has_fulltext":false,"cited_by_count":159,"reviewed_by_count":0,"citation_normalized_percentile":{"value":0.97560132,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":87,"max":99},"biblio":{"volume":"11","issue":"3","first_page":"251","last_page":"265"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10537","display_name":"Attention Deficit Hyperactivity Disorder","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10537","display_name":"Attention Deficit Hyperactivity Disorder","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12547","display_name":"Pharmaceutical studies and practices","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2735","display_name":"Pediatrics, Perinatology and Child Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T14104","display_name":"Developmental and Educational Neuropsychology","score":0.0,"subfield":{"id":"https://openalex.org/subfields/3206","display_name":"Neuropsychology and Physiological Psychology"},"field":{"id":"https://openalex.org/fields/32","display_name":"Psychology"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/atomoxetine","display_name":"atomoxetine","score":1.0},{"id":"https://openalex.org/keywords/attention-deficit-hyperactivity-disorder","display_name":"attention deficit hyperactivity disorder","score":0.9980000257492065},{"id":"https://openalex.org/keywords/children-with-adhd","display_name":"children with ADHD","score":0.8679999709129333},{"id":"https://openalex.org/keywords/noradrenergic-reuptake-inhibitors","display_name":"noradrenergic reuptake inhibitors","score":0.9129999876022339},{"id":"https://openalex.org/keywords/dose-titration","display_name":"dose titration","score":0.9549999833106995},{"id":"https://openalex.org/keywords/drug-tolerability","display_name":"drug tolerability","score":0.7680000066757202},{"id":"https://openalex.org/keywords/adhd-symptom-reduction","display_name":"ADHD symptom reduction","score":0.7789999842643738},{"id":"https://openalex.org/keywords/adhd-rating-scale-iv","display_name":"ADHD Rating Scale-IV","score":0.906000018119812},{"id":"https://openalex.org/keywords/cardiovascular-parameters","display_name":"cardiovascular parameters","score":0.5540000200271606}],"concepts":[{"id":"https://openalex.org/C2778781522","wikidata":"https://www.wikidata.org/wiki/Q417240","display_name":"Atomoxetine","level":4,"score":0.9960371851921082},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.8828153014183044},{"id":"https://openalex.org/C2909253567","wikidata":"https://www.wikidata.org/wiki/Q417240","display_name":"Atomoxetine hydrochloride","level":5,"score":0.7853888273239136},{"id":"https://openalex.org/C2780783007","wikidata":"https://www.wikidata.org/wiki/Q181923","display_name":"Attention deficit hyperactivity disorder","level":2,"score":0.6949421167373657},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.6762593984603882},{"id":"https://openalex.org/C83849319","wikidata":"https://www.wikidata.org/wiki/Q7295720","display_name":"Rating scale","level":2,"score":0.48411640524864197},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.4741216003894806},{"id":"https://openalex.org/C15744967","wikidata":"https://www.wikidata.org/wiki/Q9418","display_name":"Psychology","level":0,"score":0.43079569935798645},{"id":"https://openalex.org/C187212893","wikidata":"https://www.wikidata.org/wiki/Q123028","display_name":"Pediatrics","level":1,"score":0.3726333975791931},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.3442288041114807},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.29280874133110046},{"id":"https://openalex.org/C2777112843","wikidata":"https://www.wikidata.org/wiki/Q422112","display_name":"Methylphenidate","level":3,"score":0.2653125524520874},{"id":"https://openalex.org/C138496976","wikidata":"https://www.wikidata.org/wiki/Q175002","display_name":"Developmental psychology","level":1,"score":0.05209055542945862}],"mesh":[{"descriptor_ui":"D000069445","descriptor_name":"Atomoxetine Hydrochloride","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000293","descriptor_name":"Adolescent","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000928","descriptor_name":"Antidepressive Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D000928","descriptor_name":"Antidepressive Agents","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D000928","descriptor_name":"Antidepressive Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D001289","descriptor_name":"Attention Deficit Disorder with Hyperactivity","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D001289","descriptor_name":"Attention Deficit Disorder with Hyperactivity","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D001289","descriptor_name":"Attention Deficit Disorder with Hyperactivity","qualifier_ui":"Q000503","qualifier_name":"physiopathology","is_major_topic":false},{"descriptor_ui":"D002648","descriptor_name":"Child","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004334","descriptor_name":"Drug Administration Schedule","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004562","descriptor_name":"Electrocardiography","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006439","descriptor_name":"Hemodynamics","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D006439","descriptor_name":"Hemodynamics","qualifier_ui":"Q000502","qualifier_name":"physiology","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010349","descriptor_name":"Patient Compliance","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011437","descriptor_name":"Propylamines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D011437","descriptor_name":"Propylamines","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D011437","descriptor_name":"Propylamines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D011446","descriptor_name":"Prospective Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011581","descriptor_name":"Psychological Tests","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012720","descriptor_name":"Severity of Illness Index","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1089/10445460152595577","doi":"https://doi.org/10.1089/10445460152595577","is_oa":false,"landing_page_url":"https://doi.org/10.1089/10445460152595577","pdf_url":null,"source":{"id":"https://openalex.org/S198272637","display_name":"Journal of Child and Adolescent Psychopharmacology","issn_l":"1044-5463","issn":["1044-5463","1557-8992"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320443","host_organization_name":"Mary Ann Liebert, Inc.","host_organization_lineage":["https://openalex.org/P4310320443","https://openalex.org/P4310320017"],"host_organization_lineage_names":["Mary Ann Liebert, Inc.","SAGE Publishing"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Child and Adolescent Psychopharmacology","raw_type":"journal-article"},{"id":"pmid:11642475","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/11642475","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of child and adolescent psychopharmacology","raw_type":"Clinical Trial"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[{"id":"https://openalex.org/G4252228441","display_name":"CONTROLLED STUDY OF METHYLPHENIDATE IN ADULTS WITH ADHD","funder_award_id":"R29MH057511","funder_id":"https://openalex.org/F4320337346","funder_display_name":"National Institute of Mental Health"}],"funders":[{"id":"https://openalex.org/F4320307758","display_name":"Eli Lilly and Company","ror":"https://ror.org/01qat3289"},{"id":"https://openalex.org/F4320332161","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88"},{"id":"https://openalex.org/F4320337346","display_name":"National Institute of Mental Health","ror":"https://ror.org/04xeg9z08"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":36,"referenced_works":["https://openalex.org/W10325908","https://openalex.org/W29428084","https://openalex.org/W1209980950","https://openalex.org/W1512135897","https://openalex.org/W1594061745","https://openalex.org/W1839748132","https://openalex.org/W1963735974","https://openalex.org/W1967697510","https://openalex.org/W1979465426","https://openalex.org/W1981701086","https://openalex.org/W1984153067","https://openalex.org/W1989428478","https://openalex.org/W2002857128","https://openalex.org/W2006058627","https://openalex.org/W2016442365","https://openalex.org/W2025076170","https://openalex.org/W2032517670","https://openalex.org/W2039720389","https://openalex.org/W2040154724","https://openalex.org/W2040513075","https://openalex.org/W2051383928","https://openalex.org/W2056746076","https://openalex.org/W2070674601","https://openalex.org/W2079590493","https://openalex.org/W2083931663","https://openalex.org/W2112151032","https://openalex.org/W2116058617","https://openalex.org/W2117801294","https://openalex.org/W2123893041","https://openalex.org/W2136392208","https://openalex.org/W2140513029","https://openalex.org/W2169861403","https://openalex.org/W2328004263","https://openalex.org/W2599734864","https://openalex.org/W2946231458","https://openalex.org/W3217490374"],"related_works":["https://openalex.org/W1992714410","https://openalex.org/W2033673747","https://openalex.org/W1977031327","https://openalex.org/W4241931919","https://openalex.org/W2122518346","https://openalex.org/W2088606503","https://openalex.org/W2157382328","https://openalex.org/W1998328704","https://openalex.org/W1492384425","https://openalex.org/W2169470992"],"abstract_inverted_index":{"OBJECTIVE:":[0],"The":[1],"goal":[2],"of":[3,13,24,40,46,54,97,120,136,157,169,175,211,215],"this":[4],"study":[5,39],"was":[6,34,60,123],"to":[7,69,188],"evaluate":[8],"the":[9,14,22,44,52,84,158,163,190],"tolerability":[10],"and":[11,56,65,78,94,99,102,108],"effectiveness":[12],"experimental,":[15],"noradrenergic":[16],"specific":[17],"reuptake":[18],"inhibitor":[19],"atomoxetine":[20,41,114,212],"in":[21,43,153,162,181,195,213],"treatment":[23,45,176],"children":[25,48,82,189],"with":[26,49,91,113,147,198,203],"attention":[27],"deficit":[28],"hyperactivity":[29],"disorder":[30],"(ADHD).":[31],"METHODS:":[32],"This":[33],"an":[35],"open,":[36],"prospective,":[37],"dose-ranging":[38],"monotherapy":[42],"30":[47],"ADHD":[50,98,137,182,199],"between":[51],"ages":[53],"7":[55],"14":[57],"years.":[58],"Atomoxetine":[59,131],"started":[61],"at":[62],"10-20":[63],"mg/day":[64],"titrated":[66],"weekly":[67,92],"up":[68],"90":[70],"mg":[71],"over":[72],"11":[73,86],"weeks,":[74],"depending":[75],"on":[76],"response":[77],"adverse":[79,104,129],"effects.":[80,130],"Twenty-two":[81],"completed":[83,172],"full":[85],"weeks.":[87],"We":[88],"assessed":[89],"efficacy":[90],"clinician":[93],"parent":[95],"ratings":[96],"oppositional":[100],"symptoms":[101,135],"monitored":[103],"effects,":[105],"laboratory":[106],"findings,":[107],"cardiovascular":[109],"parameters.":[110],"RESULTS:":[111],"Treatment":[112],"(mean":[115],"final,":[116],"total":[117],"daily":[118],"dose":[119],"1.9":[121],"mg/kg/day)":[122],"very":[124],"well":[125],"tolerated":[126],"without":[127],"meaningful":[128],"significantly":[132],"reduced":[133],"core":[134],"(ADHD-Rating":[138],"Scale-IV;":[139],"38.6%":[140],"decrease":[141,180],"vs.":[142],"baseline,":[143],"p":[144],"<":[145,151],"0.001)":[146],"significant":[148],"improvement":[149],"(p":[150],"0.05)":[152],"all":[154],"but":[155],"1":[156],"18":[159],"individual":[160],"items":[161],"ADHD-Rating":[164],"Scale-IV.":[165],"More":[166],"than":[167],"75%":[168],"subjects":[170],"who":[171,200],"10":[173],"weeks":[174],"showed":[177],">":[178],"25%":[179],"symptoms.":[183],"CONCLUSIONS:":[184],"These":[185,205],"findings":[186],"extend":[187],"positive":[191],"results":[192,206],"previously":[193],"reported":[194],"adults":[196],"diagnosed":[197],"were":[201],"treated":[202],"atomoxetine.":[204],"support":[207],"additional":[208],"controlled":[209],"trials":[210],"cases":[214],"pediatric":[216],"ADHD.":[217]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2083338868","counts_by_year":[{"year":2025,"cited_by_count":2},{"year":2023,"cited_by_count":3},{"year":2022,"cited_by_count":6},{"year":2021,"cited_by_count":3},{"year":2020,"cited_by_count":2},{"year":2018,"cited_by_count":3},{"year":2017,"cited_by_count":1},{"year":2016,"cited_by_count":5},{"year":2015,"cited_by_count":5},{"year":2014,"cited_by_count":14},{"year":2013,"cited_by_count":6},{"year":2012,"cited_by_count":7}],"updated_date":"2026-11-16T12:05:36.265796","created_date":"2016-06-24T00:00:00"}
